Optimal sampling time-point for cyclosporin A concentration monitoring in heart transplant recipients.
In conclusion, C2 is an ideal time-point for monitoring plasma CsA levels with a utility for individualising the next scheduled dose for each patient to ensure that target levels are maintained and achieve a high efficacy and safety of CsA therapy in heart transplant recipients (clinical trial no. 12002610).
PMID: 30402164 [PubMed]
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
More News: Bone Graft | Cardiology | Clinical Trials | General Medicine | Heart | Heart Transplant | Men | Study | Transplant Surgery | Transplants